A new rule has been made by the government that helps people get their medical treatments faster. Sometimes, doctors need permission from insurance companies before they can give patients the treatment they need. This process is called prior authorization. The new rule makes it so that insurance companies have to say yes or no within a few days and also tell why they said no if they did. This way, people don't have to wait too long for their treatments and it helps save money too. Read from source...

- The article does not provide any data or evidence on how the new rule will streamline prior authorization processes for Medicare patients. It only cites CMS estimates of $15 billion in savings over ten years, which is vague and unverifiable.
- The article uses emotive language such as "limbo" and quotes HHS Secretary Xavier Becerra who says the new rule will help reduce wait times for approval by insurance companies. However, this does not address the underlying issue of why prior authorization is necessary in the first place, or how it affects patient care and outcomes.
- The article mentions that some payers will have to cut their decision timeframes in half, but does not specify which payers or how this will impact their operational efficiency and capacity. It also ignores the possibility of increased administrative costs or errors due to faster decision making.
- The article briefly touches on the issue of rising drug costs for Medicare Part D beneficiaries, but does not explore how the new rule will affect their access to affordable medications, or whether it will address the root causes of high drug prices such as patent protections, market competition, or regulatory barriers.
- The article ends with a positive note on the 2022 Inflation Reduction Act and its potential impact on reducing out-of-pocket expenses for Medicare Part D enrollees, but does not connect this to the main topic of prior authorization reform, or explain how it will benefit patients in the long run.

Possible answers:

- One possible way to invest in the healthcare sector is to buy stocks of companies that provide services or products related to prior authorization, electronic exchange of health information, or medication adherence. For example, some potential candidates are Change Healthcare (CHNG), Optum (UNH), Cerner (CERN), or Express Scripts (CNMD). These companies could benefit from the increased demand for their services and the new rule that aims to streamline prior authorization processes. However, there is also a risk of regulatory changes, competition, or market fluctuations that could affect their performance.
- Another possible way to invest in the healthcare sector is to buy stocks of companies that are involved in the development and production of generic drugs. For example, some potential candidates are Teva Pharmaceutical (TEVA), Mylan (MYL), or Lannett Company (LCNA). These companies could benefit from the growing market for generic drugs and the new legislation that caps out-of-pocket expenses for Medicare Part D beneficiaries. However, there is also a risk of patent litigation, pricing pressure, or supply chain disruptions that could affect their performance.
- A third possible way to invest in the healthcare sector is to buy stocks of companies that are involved in the research and development of new drugs and therapies. For example, some potential candidates are Pfizer (PFE), Moderna (MRNA), or Biogen (BIIB). These companies could benefit from the innovation and discovery of new treatments for various diseases and conditions. However, there is also a risk of clinical trial failures, regulatory hurdles, or competition that could affect their performance.